Form 8-K - Current report:
SEC Accession No. 0000310158-22-000006
Filing Date
2022-03-25
Accepted
2022-03-25 16:14:51
Documents
14
Period of Report
2022-03-22
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrk-20220322.htm   iXBRL 8-K 46112
2 EXHIBIT-3.1: BY-LAWS AS AMENDED MARCH 22, 2022 exhibit31-byxlawsasamended.htm EX-3.1 117807
  Complete submission text file 0000310158-22-000006.txt   390446

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrk-20220322.xsd EX-101.SCH 3334
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrk-20220322_def.xml EX-101.DEF 16894
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrk-20220322_lab.xml EX-101.LAB 34047
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrk-20220322_pre.xml EX-101.PRE 17690
8 EXTRACTED XBRL INSTANCE DOCUMENT mrk-20220322_htm.xml XML 19576
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 22771529
SIC: 2834 Pharmaceutical Preparations